GlassScriptPhysician profile
Mohammad Yousuf
NPI 1881634103
$12,232.91
in general payments reported to CMS, 2019-2025
47 companies · $1,543 in 2025
The $1,543 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,512 · 2020: $1,595 · 2021: $1,839 · 2022: $1,747 · 2023: $1,576 · 2024: $2,421 · 2025: $1,543.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,790 · Consulting Fee: $1,500 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,789.85 |
| Consulting Fee | $1,500.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,291.43 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $1,499.90 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $909.35 | 2020-2025 | Ubrelvy, Vraylar, Linzess |
| Amgen INC. | $748.49 | 2019-2025 | Otezla, Repatha, Repatha |
| Mylan Specialty L.P. | $743.44 | 2019-2024 | Yupelri |
| Sunovion Pharmaceuticals INC. | $613.37 | 2019-2022 | |
| Novo Nordisk INC | $544.20 | 2020-2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $474.44 | 2019-2023 | Verquvo, Belsomra, Lagevrio |
| Bayer Healthcare Pharmaceuticals INC. | $447.69 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $387.62 | 2019-2025 | Rexulti |
| Lilly USA, LLC | $360.34 | 2019-2024 | Mounjaro |
| Teva Pharmaceuticals USA, INC. | $328.61 | 2020-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $233.99 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $214.37 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $205.22 | 2019-2023 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Yousuf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.